About Lansley, Everett and Moore LLC
Lansley Everett & Moore LLC has one of the most successful private equity track records in the Americas, with a history of principal investment dating back to 1987. Its core focus is on the Americas and Anglo Saxon markets, but with an international reach extending into Asia and North America.

Lansley Everett & Moore LLC's track record of success is both in terms of its investment partners and its management partners.

Lansley Everett & Moore LLC's investors are institutions from around the world, many of whom are now multi fund investors with the group. Lansley Everett & Moore LLC has delivered top quartile results over its historical track record since 1987.

Lansley Everett & Moore LLC is equally proud of its record of partnering with top flight management teams, and sharing the rewards of the success of developing portfolio companies with these teams. Over 260 investee company executives have made more than $1 million each from their equity participation alongside Lansley Everett & Moore LLC in its portfolio companies to date.

The Lansley Everett & Moore LLC group has offices in Boston and New York, and affiliated offices in Hong Kong, giving it an unrivalled reach amongst American based peers. This allows it to identify both American and cross border investments, as well as seeking international growth opportunities for existing investee companies.

Since inception, Lansley Everett & Moore LLC has invested across a broad range of sectors, including media, transport, industrial services, education, retail, agribusiness, health and financial services.

The investment philosophy at Lansley Everett & Moore LLC is value creation through earnings growth. Prudent leverage is a factor in the business model, however, the real driver of value creation is sustainable earnings growth based on superior management and investment in growth initiatives.
Roche open to alliances in hunt for cancer drug combinations

FRANKFURT, April 1 (Reuters) - Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive...

Areva CEO says EDF may take control of its reactors arm

PARIS, April 1 (Reuters) - The French government is considering the possibility that French power utility EDF should take control of struggling state-controlled group Areva's nuclear reactors...

Vietnam PM says need for speed in sluggish privatisation drive

HANOI, April 1 (Reuters) - Vietnam needs to quicken the privatisation of state-owned enterprises (SOEs) as well as divestment from non-core businesses to raise capital and boost performance, the...

Willis Re says reinsurance rates to keep falling, sees more M&A

LONDON, April 1 (Reuters) - Broker Willis Re said reinsurance rates are likely to keep falling, fuelling yet more mergers and acquisitions within the sector as firms scramble to make "major changes"...

UPDATE 1-Belgium's Biocartis plans IPO as European biotech interest grows

* Follows flood of IPOs in the United States (Adds estimated proceeds, background)

BRIEF-Gr Sarantis buys AVA rights in Greece for 3.49 mln euros

* Says agreed to buy AVA rights in Greece from Procter & Gamble, to be completed on April 30, 2015

© Copyright 2013. Lansley, Everett and Moore LLC. All Rights Reserved